Cargando…
A Virosomal Malaria Peptide Vaccine Elicits a Long-Lasting Sporozoite-Inhibitory Antibody Response in a Phase 1a Clinical Trial
OBJECTIVES: Peptides delivered on the surface of influenza virosomes have been shown to induce solid humoral immune responses in experimental animals. High titers of peptide-specific antibodies were also induced in a phase 1a clinical trial in volunteers immunized with virosomal formulations of two...
Autores principales: | Okitsu, Shinji L., Silvie, Olivier, Westerfeld, Nicole, Curcic, Marija, Kammer, Andreas R., Mueller, Markus S., Sauerwein, Robert W., Robinson, John A., Genton, Blaise, Mazier, Dominique, Zurbriggen, Rinaldo, Pluschke, Gerd |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2093993/ https://www.ncbi.nlm.nih.gov/pubmed/18060072 http://dx.doi.org/10.1371/journal.pone.0001278 |
Ejemplares similares
-
A Randomized Placebo-Controlled Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Synthetic Peptides in Healthy Adult Volunteers
por: Genton, Blaise, et al.
Publicado: (2007) -
Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations
por: Tamborrini, Marco, et al.
Publicado: (2011) -
Virosome-Formulated Plasmodium falciparum AMA-1 & CSP Derived Peptides as Malaria Vaccine: Randomized Phase 1b Trial in Semi-Immune Adults & Children
por: Cech, Patrick Georges, et al.
Publicado: (2011) -
Design and pre-clinical profiling of a Plasmodium falciparum MSP-3 derived component for a multi-valent virosomal malaria vaccine
por: Tamborrini, Marco, et al.
Publicado: (2009) -
Evidence of Blood Stage Efficacy with a Virosomal Malaria Vaccine in a Phase IIa Clinical Trial
por: Thompson, Fiona M., et al.
Publicado: (2008)